Bell Potter’s 'Blood on the Street' analysis reveals a concerning trend for CSL Ltd (ASX: CSL) as its biopharma shares face significant challenges. The company has been downgraded from a hold rating to a negative yield recommendation, signaling a sharp decline in its future performance. This downgrade coincides with a major revenue shortfall—$750m in FY26 guidance—and a weakened gross margin, raising concerns about its ability to recover from past losses. The recent update to Behring GM further exacerbates these worries, as investors question whether the company can return to pre-COVID levels of gross margins by FY27. Additionally, the U.S. Ig plasma market has seen oversupply, leading to reduced market share and increased competition among players like Grifols. These factors are contributing to a broader downward spiral in CSL’s valuation, which has been tempered by a modest increase in its price-to-earnings ratio and a reduction in its target multiple. While Bell Potter highlights the importance of maintaining a hold, he emphasizes the need to account for the declining earnings outlook and the potential risks posed by management instability. Overall, the situation underscores the fragility of CSL’s position in a sector facing both internal and external pressures.
